Lung Cancer :: Nanoparticle tumor suppressor shows promise
Laboratory results with the NPRL2 tumor suppressor gene demonstrated that infusions of NPRL2 nanoparticles in combination with cisplatin resulted in a 90 percent inhibition of tumor growth in human lung cancer cells compared to control treatments, reported Introgen Therapeutics, Inc. (Nasdaq: INGN – News).